Royce & Associates’s OmniAb OABI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-867,080
Closed -$1.51M 817
2025
Q2
$1.51M Buy
867,080
+50,000
+6% +$83.7K 0.02% 633
2025
Q1
$1.96M Buy
817,080
+110,000
+16% +$360K 0.02% 592
2024
Q4
$2.5M Buy
707,080
+575,796
+439% +$2.28M 0.02% 597
2024
Q3
$555K Sell
131,284
-2,039
-2% -$8.82K 0.01% 793
2024
Q2
$500K Buy
133,323
+28,735
+27% +$131K ﹤0.01% 789
2024
Q1
$567K Sell
104,588
-55,560
-35% -$320K 0.01% 781
2023
Q4
$988K Buy
160,148
+114,485
+251% +$563K 0.01% 738
2023
Q3
$237K Buy
+45,663
New +$244K ﹤0.01% 864

Other funds holding OABI

Royce & Associates's OABI Position: Q3 2025 in Review

Royce & Associates sold out of OmniAb (OABI) in Q3 2025, closing a stake of 867,080 shares — an estimated $1.51M sold.

Royce & Associates first reported a position in OABI in Q3 2023 and held it in 8 quarters. The position peaked at $2.5M in Q4 2024. 140 funds tracked by Wall St. Rank hold OABI as of Q3 2025.

  • Royce & Associates reported no remaining OmniAb position as of Q3 2025 after selling out during the quarter.
  • Royce & Associates sold 867,080 OmniAb shares in Q3 2025, an estimated $1.51M.
  • Royce & Associates first reported a position in OmniAb in Q3 2023 and held it in 8 quarters.
  • Royce & Associates's OmniAb position peaked at $2.5M in Q4 2024.
  • 140 funds tracked by Wall St. Rank held OmniAb as of Q3 2025.

Based on Royce & Associates's 13F filing for Q3 2025, filed 12 Nov 2025.